Honorary Principal Investigator
The Immunoregulation Group in the Centre for Molecular and Cellular Biology of Inflammation
Reader in the Academic Department of Rheumatology
This laboratory group has extensive experience in cellular immunology predominantly investigating the role of T cells, macrophages/monocytes and synovial fibroblasts, either individually or through cell-to-cell interactions, in the chronic inflammation of rheumatoid arthritis and other inflammatory arthritides.
The laboratory was the first to describe the pivotal importance of the T cell in the pathogenesis of RA. Since then additional projects have highlighted (1), that the poor recall antigen T cell response in RA is correlated with the relative amounts of IL-2 and IL-10 produced, (2) the abnormal expression of early and late activation molecules by synovial fluid T cells indicative of a recirculating population of T cells and (3) FLS induced anergy in T cells and the fact that these anergic T cells remain pro-inflammatory.
Since 2000 our research has been focussed on the study of the immunobiology of BiP, a stress protein and molecular chaperone. This project has spanned almost 10 years and has taken us from the bench to the bedside as a genuinely translational project. After initial discovery as a putative autoantigen in rheumatoid arthritis we have carried out extensive research into the function of this molecule and are about to take BiP into a Phase I/IIa clinical trial.
Selected recent publications
Shields AM, Klavinskis LS, Antoniou M, Wooley PH, Collins HL, Panayi GS, Thompson SJ, Corrigall VM. Systemic gene transfer of binding immunoglobulin protein (BiP) prevents disease progression in murine collagen-induced arthritis. Clin Exp Immunol. 2015 Feb;179(2):210-9.
Panayi GS, Corrigall VM. Immunoglobulin heavy-chain-binding protein (BiP): a stress protein that has the potential to be a novel therapy for rheumatoid arthritis. Biochem Soc Trans. 2014 Dec;42(6):1752-5
Ceeraz S, Hall C, Choy EH, Spencer J, Corrigall VM. Defective CD8+CD28+ regulatory T cell suppressor function in rheumatoid arthritis is restored by tumour necrosis factor inhibitor therapy. Clin Exp Immunol. 2013Oct;174(1):18-26.
Strollo R, Ponchel F, Malmström V, Rizzo P, Bombardieri M, Wenham CY, Landy R, Perret D, Watt F, Corrigall VM, Winyard PG, Pozzilli P, Conaghan PG, Panayi GS, Klareskog L, Emery P, Nissim A. Autoantibodies to posttranslationally modified type II collagen as potential biomarkers for rheumatoid arthritis. Arthritis Rheum. 2013 Jul;65(7):1702-12.
Shields AM, Panayi GS, Corrigall VM. A New-Age for Biologic Therapies: Long-Term Drug-Free Therapy with BiP? Front Immunol. 2012 Feb 17;3:17.